Protara Therapeutics (TARA) Non Operating Interest Expenses (2014 - 2018)

Protara Therapeutics (TARA) has 5 years of Non Operating Interest Expenses data on file, last reported at $411000.0 in Q4 2018.

• On a quarterly basis, Non Operating Interest Expenses rose 3.01% year-over-year to $411000.0 in Q4 2018; TTM through Dec 2018 was $411000.0, a 3.01% increase from a year earlier, with the FY2018 full-year figure at $411000.0, up 3.01% from the prior year.
• Non Operating Interest Expenses for Q4 2018 stood at $411000.0, up from $399000.0 in the prior quarter.
• Over the last five years, Non Operating Interest Expenses for TARA reached as high as $544000.0 in Q4 2016 and fell as low as $27000.0 in Q4 2015.
• Historically, Non Operating Interest Expenses has averaged $371800.0 across 5 years, with a median of $411000.0 in 2018.
• Across the five-year window, Non Operating Interest Expenses slumped 94.35% in 2015 and jumped 1914.81% in 2016, its largest moves.
• Year by year, Non Operating Interest Expenses stood at $478000.0 in 2014, then slumped by 94.35% to $27000.0 in 2015, then soared by 1914.81% to $544000.0 in 2016, then decreased by 26.65% to $399000.0 in 2017, then climbed by 3.01% to $411000.0 in 2018.
• Per Business Quant data, the three most recent Non Operating Interest Expenses figures were $411000.0 in Q4 2018, $399000.0 in Q4 2017, and $544000.0 in Q4 2016.